Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 379
Filtrar
1.
Biodegradation ; 34(3): 253-262, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-36797384

RESUMO

In the present study, the potential inhibitory effect of biologically pre-treated vegetable tannery wastewater (TW) on anammox granular biomass was evaluated. Beside high organic and chemicals load, vegetable TW are characterised by high salinity and high tannins concentration, the latter belonging to a group of bio-refractory organic compounds, potentially inhibitory for several bacterial species. Recalcitrant tannin-related organic matters and salinity were selected as the two potential inhibitory factors and studied either for their separate and combined effect. Parallel batch tests were performed, with biomass acclimated and non-acclimated to salinity, testing three different conditions: non-saline control test with non-acclimated biomass (CT); saline control test with acclimated biomass (SCT); vegetable tannery wastewater test with acclimated biomass (TWT). Compared with non-saline CT, the specific anammox activity in tests SCT and TWT showed a reduction of 28 and 14%, respectively, suggesting that salinity, at conductivity values of 10 mS/cm (at 25 °C), was the main impacting parameter. As a general conclusion, the study reveals that there is no technical limitation for the application of the anammox process to vegetable TW, but preliminary biomass acclimation as well as regular biomass activity monitoring is recommended in case of long-term applications. To the best of our knowledge, this is the first work assessing the impact of vegetable TW on anammox biomass.


Assuntos
Compostos de Amônio , Águas Residuárias , Verduras , Reatores Biológicos/microbiologia , Nitrogênio , Biomassa , Desnitrificação , Oxidação Anaeróbia da Amônia , Oxirredução , Anaerobiose
2.
J Eur Acad Dermatol Venereol ; 35(11): 2118-2120, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34647666
7.
Artigo em Inglês | MEDLINE | ID: mdl-32746604

RESUMO

This article has been retracted at the request of the Editor. After a thorough investigation the Editor-in-Chief has retracted this article as it showed evidence of substantial manipulation of the peer review.

8.
Artigo em Inglês | MEDLINE | ID: mdl-32668870

RESUMO

Ahead of Print article withdrawn by publisher.

12.
J Biol Regul Homeost Agents ; 33(3): 817-819, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31184104

RESUMO

Pattern hair loss (i.e., androgenetic alopecia) is a common condition afflicting approximately fifty percent of men and women by the age of fifty. Currently, topical minoxidil is the only US FDA approved drug for the treatment of pattern hair loss in men and women.


Assuntos
Alopecia/tratamento farmacológico , Minoxidil/farmacologia , Sulfotransferases/metabolismo , Feminino , Humanos , Masculino
14.
Dermatol Ther ; 31(6): e12741, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30226287

RESUMO

Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA). Minoxidil is a pro-drug converted into its active form, minoxidil sulfate, by the sulfotransferase enzymes in the outer root sheath of hair follicles. Previously, we demonstrated that sulfotransferase activity in hair follicles predicts response to topical minoxidil in the treatment of AGA. In the human liver, sulfotransferase activity is significantly inhibited by salicylic acid. Low-dose OTC aspirin (75-81 mg), a derivative of salicylic acid, is used by millions of people daily for the prevention of coronary heart disease and cancer. It is not known whether oral aspirin inhibits sulfotransferase activity in hair follicles, potentially affecting minoxidil response in AGA patients. In the present study, we determined the follicular sulfotransferase enzymatic activity following 14 days of oral aspirin administration. In our cohort of 24 subjects, 50% were initially predicted to be responders to minoxidil. However, following 14 days of aspirin administration, only 27% of the subjects were predicted to respond to topical minoxidil. To the best of our knowledge, this is the first study to report the effect of low-dose daily aspirin use on the efficacy of topical minoxidil.


Assuntos
Alopecia/tratamento farmacológico , Aspirina/administração & dosagem , Inibidores Enzimáticos/administração & dosagem , Folículo Piloso/efeitos dos fármacos , Minoxidil/administração & dosagem , Pró-Fármacos/administração & dosagem , Sulfotransferases/antagonistas & inibidores , Administração Cutânea , Adulto , Alopecia/diagnóstico , Alopecia/fisiopatologia , Aspirina/efeitos adversos , Interações Medicamentosas , Inibidores Enzimáticos/efeitos adversos , Folículo Piloso/enzimologia , Folículo Piloso/crescimento & desenvolvimento , Humanos , Masculino , Minoxidil/análogos & derivados , Minoxidil/metabolismo , Pró-Fármacos/metabolismo , Medição de Risco , Sulfotransferases/metabolismo , Resultado do Tratamento , Adulto Jovem
15.
J Biol Regul Homeost Agents ; 32(4): 937-940, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30043580

RESUMO

Minoxidil is the only US FDA-approved topical drug for the treatment of female and male pattern hair loss. Previously, it was demonstrated that topical minoxidil is metabolized to its active metabolite, minoxidil sulfate, by sulfotransferase enzymes located in the outer root sheath of hair follicles. The expression of sulfotransferase in the scalp varies greatly between individuals, and this difference in expression explains the varied response to minoxidil treatment. Previously, we have demonstrated the clinical utility of detecting sulfotransferase in plucked hair follicles to predict minoxidil response in pattern hair loss patients. Typically, exogenous exposure to substrates affects the expression of the enzymatic system responsible for their metabolism. For example, Phase I metabolizing enzymes, such as the cytochrome P450 family of enzymes, are known to be up-regulated in the presence of xenobiotic substrates. However, it is not known if Phase II metabolizing enzymes, such as the sulfotransferase family of enzymes, are similarly affected by the presence of substrates. In this study, we recruited 120 subjects and analyzed their sulfotransferase enzymatic activity before and after treatment with topical minoxidil. Adjusting the results for biologic (within subject) variability, we discovered that the sulfotransferase enzymatic system expression is stable over the course of minoxidil treatment. To the best of our knowledge, this is the first study to demonstrate the stability of sulfotransferase, a Phase II metabolizing enzyme, over the course of minoxidil treatment.


Assuntos
Folículo Piloso/efeitos dos fármacos , Folículo Piloso/enzimologia , Minoxidil/metabolismo , Minoxidil/uso terapêutico , Sulfotransferases/metabolismo , Administração Tópica , Adulto , Alopecia/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
16.
J Biol Regul Homeost Agents ; 31(4): 1013-1016, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29254307

RESUMO

In recent years, dermatologists have observed an increase in the incidence of male androgenetic alopecia (AGA). In a survey of 41 dermatologists, 88% reported an increase in incidence of AGA in men younger than 30 years. This phenomenon has no apparent explanation. However, due to the strong genetic inheritance component of AGA, a social or environmental factor which favours the inheritance of genes that increase the risk of developing AGA is suspected. To date, the strongest predictor of AGA in men has been the length of the CAG repeat located in the androgen receptor gene (AR gene) on the X chromosome. The same genetic variant in women is associated with ovulation at a later age, higher antral follicle count, and lower risk for premature ovarian failure. This led us to theorize that, due to social pressure to conceive later in life, women carriers of the short CAG repeat in the AR gene would have a selective advantage to conceive later in life and would thus favour male offspring exhibiting AGA.


Assuntos
Alopecia/genética , Predisposição Genética para Doença , Herança Materna , Receptores Androgênicos/genética , Adulto , Fatores Etários , Alopecia/diagnóstico , Cromossomos Humanos X/química , Cromossomos Humanos X/metabolismo , Feminino , Fertilização/genética , Expressão Gênica , Humanos , Masculino , Folículo Ovariano/citologia , Folículo Ovariano/fisiologia , Ovulação/genética , Receptores Androgênicos/química , Seleção Genética , Fatores Socioeconômicos , Repetições de Trinucleotídeos
17.
J Biol Regul Homeost Agents ; 31(4): 1037-1041, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29254311

RESUMO

Depression and mood disorders often develop after dermatological conditions which could be primary or secondary to dermatological pathology. The oxidative and psychological stress cause physiological changes in the body. Shift in the methylation pathway, elevated cortisol, lowered neurotransmitter levels and lowered immune system allow infection to penetrate the body and lead to anxiety and depression. Here, a case report of a 20 year old male patient is presented to show how infectious skin lesions, unresponsive to the usual treatment plan, were treated after using a multipronged approach of addressing systemic infection of Escherichia coli, elevated cortisol levels and nutritional imbalances.


Assuntos
Ansiedade/psicologia , Depressão/psicologia , Infecções por Escherichia coli/psicologia , Dermatopatias Bacterianas/psicologia , Estresse Psicológico/psicologia , Antibacterianos/uso terapêutico , Ansiedade/complicações , Ansiedade/tratamento farmacológico , Ansiedade/microbiologia , Cefoperazona/uso terapêutico , Depressão/complicações , Depressão/tratamento farmacológico , Depressão/microbiologia , Infecções por Escherichia coli/complicações , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Humanos , Hidrocortisona/sangue , Masculino , Fosfatidilserinas/uso terapêutico , Probióticos/uso terapêutico , Dermatopatias Bacterianas/complicações , Dermatopatias Bacterianas/tratamento farmacológico , Dermatopatias Bacterianas/microbiologia , Estresse Psicológico/complicações , Estresse Psicológico/tratamento farmacológico , Estresse Psicológico/microbiologia , Sulbactam/uso terapêutico , Resultado do Tratamento , Adulto Jovem
18.
J Biol Regul Homeost Agents ; 31(4): 1049-1053, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29254313

RESUMO

Topical minoxidil is the only topical drug approved by the US Food and Drug Administration (FDA) for the treatment of androgenetic alopecia. However, the exact mechanism by which minoxidil stimulates anagen phase and promotes hair growth is not fully understood. In the late telegen phase of the hair follicle growth cycle, stem cells located in the bulge region differentiate and re-enter anagen phase, a period of growth lasting 2-6 years. In androgenetic alopecia, the anagen phase is shortened and a progressive miniaturization of hair follicles occurs, eventually leading to hair loss. Several studies have demonstrated that minoxidil increases the amount of intracellular Ca2+, which has been shown to up-regulate the enzyme adenosine triphosphate (ATP) synthase. A recent study demonstrated that ATP synthase, independent of its role in ATP synthesis, promotes stem cell differentiation. As such, we propose that minoxidil induced Ca2+ influx can increase stem cell differentiation and may be a key factor in the mechanism by which minoxidil facilitates hair growth. Based on our theory, we provide a roadmap for the development of a new class of drugs for the treatment of androgenetic alopecia.


Assuntos
Alopecia/tratamento farmacológico , Folículo Piloso/efeitos dos fármacos , Minoxidil/uso terapêutico , Mitocôndrias/efeitos dos fármacos , ATPases Mitocondriais Próton-Translocadoras/genética , Células-Tronco/efeitos dos fármacos , Vasodilatadores/uso terapêutico , Adulto , Alopecia/enzimologia , Alopecia/genética , Alopecia/patologia , Cálcio/metabolismo , Diferenciação Celular/efeitos dos fármacos , Expressão Gênica , Folículo Piloso/enzimologia , Folículo Piloso/patologia , Humanos , Transporte de Íons/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Mitocôndrias/enzimologia , ATPases Mitocondriais Próton-Translocadoras/metabolismo , Células-Tronco/enzimologia , Células-Tronco/patologia , Regulação para Cima
19.
J Biol Regul Homeost Agents ; 31(2 Suppl. 2): 35-37, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28702962

RESUMO

Neotrombicula autumnalis is an arthropod living in the soil and parasitizes animals only in its larval stage. Depending on climatic conditions, one to five life cycles can take place in a single year. Human infestation is probably underestimated and can be easily missed due to non-pathognomonic cutaneous manifestations in absence of systemic signs. We describe a case of human trombiculiasis and discuss the diagnostic and therapeutic management of this 'synanthropic' dermatosis.

20.
J Biol Regul Homeost Agents ; 31(2 Suppl. 2): 1-13, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28702959

RESUMO

The aim of the present study is to evaluate the effects on skin regeneration of a new collagen matrix (CM-10826) when used in different combination with or without growth factors, using skin regeneration without membrane as control. An area of 10x15 cm on rabbit back was shaved and three circular wounds on test side were covered with a differently soaked membrane. The first wound was soaked with Epidermal Growth Factor (EGF, 26mg/130mL) (Test EGF), the second with Platelet-Derived Growth Factor (PDGF, 6mg/120mL) (Test PDGF) and the third with EGF (13mg/65mL) and PDGF (3mg/60mL) (Test EGF+PDGF). On the control side, there was a dry membrane. After 7 days, the experiment was concluded. Healing process was evaluated at day 2 and 6 postoperatively. Analysis was made clinically and with light microscopy (LM), transmission electron microscopy (TEM) and scanning electron microscopy (SEM). Analyses with LM of Test EGF showed evidence of neoangiogenesis and good epithelium growth. Test PDGF resulted in moderate angiogenesis, less evident epithelial growth and more evident mesenchymal growth than Test EGF. Test EGF+PDGF showed rich angiogenesis, massive growth of epithelium and mesenchymal tissue. Control side showed weak angiogenesis, regenerating wound margin with normal epithelium and less dense mesenchymal layer. Analysis at TEM and SEM confirmed what was noticed at LM. In vivo studies on rabbits have shown that membrane CM10826 is well tolerated, it gives neither inflammation nor foreign body reactions and does not disturb healing process. CM10826 is safe, modulates angiogenesis and induces migration and proliferation of keratinocytes.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...